A Comprehensive Review of Chalcones in Dual-Targeted Therapeutics for the Treatment of Parkinson's Disease.
Abstract
INTRODUCTION The design of novel therapeutic entities for neurodegenerative diseases, particularly Parkinson's disease, remains a major challenge in medicinal chemistry. Current treatment strategies primarily rely on symptomatic management, often involving levodopa in combination with catechol-O-methyltransferase (COMT) inhibitors to prolong its therapeutic effect. However, these approaches do not adequately address the multifactorial nature of the disease. This study aims to explore the potential of chalcone derivatives as dual-target-directed ligands capable of modulating both COMT and adenosine A₂A receptors for improved therapeutic outcomes in Parkinson's disease.
Methods
A comprehensive analysis of chalcone-based scaffolds, particularly those incorporating heterocyclic moieties, was undertaken to evaluate their suitability as multitarget agents. Emphasis was placed on their structural versatility and ability to interact with key biological targets involved in Parkinson's disease pathology.
Results
Chalcones exhibit promising pharmacological properties, including the ability to inhibit COMT, thereby reducing levodopa metabolism, and antagonize adenosine A₂A receptors, which play a crucial role in regulating neurotransmission and motor function.
Discussion
The incorporation of heterocyclic substituents appears to enhance target affinity and selectivity, likely through improved molecular interactions within the binding site. Furthermore, the observed multitarget activity may confer synergistic therapeutic benefits by concurrently modulating multiple pathological pathways, which is particularly advantageous for the treatment of complex multifactorial diseases.
Conclusion
Chalcone derivatives represent a promising class of multitarget compounds for Parkinson's disease management. Their dual inhibitory activity against COMT and A₂A receptors, combined with their structural flexibility, supports their potential for further development as effective neuroprotective agents.